Scarica l'app Stockscreener
4.37
1.39%
0.06
Dopo l'orario di chiusura:
4.43
0.06
+1.37%
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - msn.com
Aug Patterns: Is Taysha Gene Therapies Inc undervalued by DCF analysis2026 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
TSHA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
SG Americas Securities LLC Acquires 748,525 Shares of Taysha Gene Therapies, Inc. $TSHA - marketbeat.com
Hennion & Walsh Asset Management Inc. Invests $1.70 Million in Taysha Gene Therapies, Inc. $TSHA - marketbeat.com
Should you avoid Taysha Gene Therapies Inc stock right nowProfit Target & Weekly Top Gainers Trade List - baoquankhu1.vn
Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances - MSN
Buybacks Report: Is Taysha Gene Therapies Inc undervalued by DCF analysisQuarterly Investment Review & AI Driven Stock Movement Reports - baoquankhu1.vn
Aug Catalysts: Will Taysha Gene Therapies Inc benefit from AI trendsJobs Report & Verified Momentum Stock Alerts - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Truist Financial - marketbeat.com
Panic Selling: Whats the fair value of Taysha Gene Therapies Inc stockCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Levels Update: Whats the fair value of Taysha Gene Therapies Inc stock2026 Winners & Losers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 8.5%Should You Buy? - MarketBeat
Cantor Fitzgerald reiterates Overweight on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9%Time to Sell? - MarketBeat
Taysha Gene Therapies FY 2025 earnings preview - MSN
How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story - Yahoo Finance
BMO Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA) - theglobeandmail.com
Taysha Gene Therapies Receives 'Moderate Buy' Rating from Analysts - National Today
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
Chardan Capital Maintains Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat
Decoding Taysha Gene Therapies Inc (TSHA): A Strategic SWOT Insi - GuruFocus
Taysha Gene Therapies Q4 Loss Of US$27.9m Tests Bullish TSHA 102 Narrative - simplywall.st
Taysha Gene Therapies Signals Momentum in Earnings Call - TipRanks
Taysha Gene Therapies (TSHA) Advances Rett Syndrome Treatment - GuruFocus
Jefferies raises Taysha Gene Therapies price target on trial progress By Investing.com - Investing.com Canada
Key facts: Taysha $109M loss; Q4 rev +171%; $320M cash; TSHA-102 safe, Q2'26 - TradingView
TSHA: Analyst Chardan Capital Maintains Buy Rating with $12 PT | - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Australia
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlight - GuruFocus
Taysha Gene Therapies Q4 2025 Earnings Call Transcript - MarketBeat
Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies’ Q4 Earnings Call: FDA Timeline, European Strategy Claims Don’t Match Prior Statements - Bitget
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress i - GuruFocus
Taysha Gene Therapies Q4 Earnings Call Highlights - MarketBeat
Taysha Gene Therapies 2026 Conference Call: TSHA-102 Development & Regulatory PlansNews and Statistics - IndexBox
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update - Investing News Network
TSHA: TSHA-102 advanced toward registration with strong trial data, FDA alignment, and solid cash runway - TradingView
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Taysha (TSHA) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Taysha (TSHA) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss - Investing.com Canada
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss By Investing.com - Investing.com South Africa
Taysha Gene Therapies (NASDAQ:TSHA) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Valuation Update: How correlated is Taysha Gene Therapies Inc to the S P5002026 Price Momentum & Daily Oversold Bounce Ideas - baoquankhu1.vn
Taysha Gene Therapies, Inc. Appoints Brad Martin as Senior Vice President, Market Access and Value - marketscreener.com
Taysha Gene Therapies 10-K: $9.8M Revenue, $(0.34) EPS - tradingview.com
Rett gene therapy advances at Taysha Gene Therapies (TSHA) - Stock Titan
Taysha Gene Therapies reports full-year 2025 earnings and issues corporate update - Traders Union
Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Revenue $9.8M, vs. FactSet Est of $5.9M - marketscreener.com
Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Net Loss $0.34 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Taysha Gene Therap Reports 2025 Full-Year Results — $9.8M Revenue, $109.0M Net Loss - TradingView
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):